Market Overview

Myelofibrosis - Pipeline Insights, 2018 - ResearchAndMarkets.com

Share:

The "Myelofibrosis
- Pipeline Insight, 2018"
drug pipelines has been added to ResearchAndMarkets.com's
offering.

This report offers a comprehensive Iinsight of the pipeline (under
development) therapeutics scenario and growth prospects across
Myelofibrosis development.

The report provides detailed coverage of the pipeline landscape for this
mechanism of action, equipped with data from multiple sources with
complete pipeline analysis by developmental stage, associated
indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental
Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product
profiles including (but not limited to) drug description, product
development and R&D activities encompassing clinical and pre-clinical
studies, designations, collaborations, licensing deals, grants,
technologies and patent details.

The report assesses the active Myelofibrosis pipeline products by
developmental stage, product type, molecule type, and administration
route.

Scope

  • The report provides a snapshot of the pipeline development for the
    Myelofibrosis
  • The report covers pipeline activity across the complete product
    development cycle i.e. clinical, pre-clinical and discovery stages for
    the Myelofibrosis
  • The report provides pipeline product profiles which includes product
    description, developmental activities, licensors & collaborators and
    chemical information
  • Provides pipeline assessment by monotherapy and combination therapy
    products, stage of development, route of administration, and molecule
    type for Myelofibrosis
  • The report also covers the dormant and discontinued pipeline projects
    related to the Myelofibrosis

Companies Featured

  • Acceleron Pharma
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • CTI BioPharma Corp.
  • Gilead Sciences
  • Incyte Corporation
  • Italfarmaco
  • Johnson & Johnson
  • JW Pharmaceutical Corporation
  • Novartis AG

Key Topics Covered

1. Report Introduction

2. Myelofibrosis Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Products in Clinical Stage

6. Products in Pre-Clinical and Discovery Stage

7. Therapeutic Assessment

8. Inactive Products

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/ccslw6/myelofibrosis?w=4

View Comments and Join the Discussion!